Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval
Alberto Martini(The University of Texas MD Anderson Cancer Center), Colin P. Dinney(The University of Texas MD Anderson Cancer Center), Sharada Mokkapati(The University of Texas MD Anderson Cancer Center), Côme Tholomier(The University of Texas MD Anderson Cancer Center)
Cited by 24
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease
|Annals of the Rheumatic Diseases|2001|287